PULMOTECT, INC.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.pulmotect.com
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Conditions
- Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Pulmotect, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06665100
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Pulmotect, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT04312997
- Locations
- 🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸Invesclinic US LLC, Fort Lauderdale, Florida, United States
🇺🇸DBC Research Corp., Tamarac, Florida, United States
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Pulmotect, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT04313023
- Locations
- 🇺🇸
Willis-Knighton Physcian Network, Bossier City, Louisiana, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of California Irvine, Orange, California, United States
The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD
- Conditions
- COPD
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Pulmotect, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03794557
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, St Mary Hospital, London, United Kingdom
A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Pulmotect, Inc.
- Registration Number
- NCT03097796
- Locations
- 🇺🇸
University of Texas MD Anderson MD Anderson Cancer Center, Houston, Texas, United States
Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Pulmotect, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02566252
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Pulmotect, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02124278
- Locations
- 🇺🇸
ICON Development Solutions, San Antonio, Texas, United States